LIPTRUZET Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Liptruzet, and what generic alternatives are available?
Liptruzet is a drug marketed by Organon and is included in one NDA.
The generic ingredient in LIPTRUZET is atorvastatin calcium; ezetimibe. There are sixty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the atorvastatin calcium; ezetimibe profile page.
Summary for LIPTRUZET
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LIPTRUZET |
DailyMed Link: | LIPTRUZET at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for LIPTRUZET
US Patents and Regulatory Information for LIPTRUZET
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Organon | LIPTRUZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 200153-001 | May 3, 2013 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Organon | LIPTRUZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 200153-004 | May 3, 2013 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Organon | LIPTRUZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 200153-002 | May 3, 2013 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Organon | LIPTRUZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 200153-003 | May 3, 2013 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LIPTRUZET
International Patents for LIPTRUZET
See the table below for patents covering LIPTRUZET around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Norway | 305902 | ⤷ Try a Trial | |
Taiwan | 427974 | ⤷ Try a Trial | |
South Korea | 186853 | ⤷ Try a Trial | |
Japan | 3254219 | ⤷ Try a Trial | |
European Patent Office | 1148049 | Formes cristallines d'hémi-sel de calcium d'acide r-(r*,r*) -2-(4-fluorophényl)-beta,delta-dihydroxy-5-(1-methyléthyl)-3-phényl-4- (phenylamino)carbonyl -1h-pyrrole-1-heptanoique (atorvastatine) (Crystalline R-(R*,R*)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)) | ⤷ Try a Trial |
Australia | 725424 | ⤷ Try a Trial | |
New Zealand | 274041 | SUBSTITUTED 1,4-DIARYL-3-ARALKYL-AZETIDIN-2-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LIPTRUZET
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0720599 | SPC/GB03/023 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: EZETIMIBE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: DE 54486.00.00 20021017; DE 54488.00.00 20021017; DE 54487.00.00 20021017; DE 54489.00.00 20021017; UK PL 19945/0001 20030404; UK PL 19945/0002 20030404 |
0720599 | CA 2005 00003 | Denmark | ⤷ Try a Trial | |
0720599 | 20/2003 | Austria | ⤷ Try a Trial | PRODUCT NAME: EZETIMIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; NAT. REGISTRATION NO/DATE: 1-24902 1-24904 20030415; FIRST REGISTRATION: DE 54486.00.00 - 54489.00.00 20021017 |
1003503 | 05C0048 | France | ⤷ Try a Trial | PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707 |
0247633 | 62/1997 | Austria | ⤷ Try a Trial | PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107 |
0720599 | 91160 | Luxembourg | ⤷ Try a Trial | 91160, EXPIRES: 20190914 |
0720599 | SPC/GB05/010 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: EZETIMIBE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH SIMVASTATIN; REGISTERED: DE 58874.00.00 20040402; DE 58874.01.00 20040402; DE 58874.02.00 20040402; DE 58874.03.00 20040402; DE 58878.00.00 20040402; DE 58878.01.00 20040402; DE 58878.02.00 20040402; DE 58878.03.00 20040402; DE 58866.00.00 20040402; DE 58866.01.00 20040402; DE 58866.02.00 20040402; DE 58866.03.00 20040402; DE 58870.00.00 20040402; DE 58870.01.00 20040402; DE 58870.02.00 20040402; DE 58870.03.00 20040402; UK PL 19945/0003 20041118; UK PL 19945/0004 20041118; UK PL 19945/0005 20041118; UK PL 19945/0006 20041118; UK PL 19945/0007 20041118; UK PL 19945/0008 20041118; UK PL 19945/0009 200411 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |